Rhythm Biosciences Secures First Southeast Asia Distribution Deal for geneType
Rhythm Biosciences is a pioneering medical diagnostics company listed on the Australian Securities Exchange (ASX:RHY), dedicated to transforming cancer detection through innovative blood-based technologies. Their mission is to revolutionize early cancer screening by developing advanced diagnostic tools that can predict, detect, characterize, and support early intervention for various cancer types, ultimately aiming to improve patient outcomes and reduce healthcare costs.
The company’s flagship product, ColoSTAT®, is a groundbreaking blood test designed for the early detection of colorectal cancer, currently in development. Complementing this is their geneType™ platform, a world-leading personalized predictive test that utilizes a unique combination of genomic and clinical information to assess an individual’s risk of chronic disease development. These technologies represent Rhythm Biosciences’ commitment to creating comprehensive, scientifically rigorous, and accessible testing solutions that can potentially save lives through early detection.
Located in the Bio21 Institute in Parkville, Victoria, Rhythm Biosciences is at the forefront of medical innovation, leveraging cutting-edge scientific research to develop high-quality diagnostic solutions. Their approach is underpinned by robust scientific, clinical, and economic evidence, with a clear vision of making cancer screening more effective, less invasive, and more widely available. By focusing on early detection and risk assessment, the company is working to transform the landscape of cancer diagnostics and provide hope for improved patient outcomes globally.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
